Subscribe free

Cytoreductive Surgery & Peritoneum ·

CRS/HIPEC Improves Survival in Low-Grade Appendiceal Carcinoma

CRS/HIPEC significantly enhances survival for select low-grade appendiceal carcinoma patients with peritoneal and parenchymal metastases.

  • Median overall survival (OS) for low-grade mucinous and non-mucinous patients after CRS/HIPEC was not reached, compared to 50 months for surgery alone and 26 months for systemic chemotherapy (p < 0.01).
  • In multivariable analysis, CRS/HIPEC reduced mortality risk for low-grade mucinous (HR 0.48) and non-mucinous (HR 0.15) cases (p < 0.01).

Consider CRS/HIPEC for suitable low-grade cases to improve patient outcomes.

Journal Article by Baron E, Wu CC, Wernberg JA and Sharma R in Eur J Surg Oncol

Copyright © 2025 Elsevier Ltd, BASO ~ The Association for Cancer Surgery, and the European Society of Surgical Oncology. All rights reserved.

read the whole article in Eur J Surg Oncol

open it in PubMed

Summaries are written to help you decide what to read. They do not replace the full paper.

Free · 5 minutes a day

Get every new paper in Cytoreductive Surgery & Peritoneum.

Plus the Daily Selection: the five most relevant papers of the day, each cut to its key points.

Specialty newsletters: every new paper in your field, as a list of titles linked to the source. Daily Selection: the five that matter, cut to their key points.

FreeNo spamOne-click unsubscribe

More in Cytoreductive Surgery & Peritoneum

The latest stitches

Ann Surg Oncol28 Aug 2026

Prophylactic HIPEC Improves Survival in Advanced Colorectal Cancer

Prophylactic hyperthermic intraperitoneal chemotherapy (HIPEC) significantly enhances peritoneal metastasis-free survival and disease-free survival in patients with locally advanced colorectal cancer, though overall survival rates and complication rates remain unchanged.

All papers in Cytoreductive Surgery & Peritoneum →